Meltrins
AssigneeMochida Pharmaceutical Co., Ltd.
InventorsAtsuko Fujisawa, Toru Yamakawa, Kamon Shirakawa, Chitose Orii, Naoki Ogawa
Life of this patent
Estimating the term…
Loading patent…
AssigneeMochida Pharmaceutical Co., Ltd.
InventorsAtsuko Fujisawa, Toru Yamakawa, Kamon Shirakawa, Chitose Orii, Naoki Ogawa
Estimating the term…
The purpose of the present invention is to provide a novel protein involved in adhesion and fusion between myoblasts in the course of the formation of byotube. The present invention relates to Meltrins, which a membrane protein having fusion, adhesion and aggregation activity of cells, especially myoblast; and to polypeptides of their domains, DNAs encoding them, antisense RNA for these DNAs, various antibodies to Meltrins and the polypeptides of their domains, expression vectors containing these DNAs, and transformants by these vectors; as well as to the process for producing Meltrins and the polypeptides of their domains using those transformants and medical compositions comprising Meltrins or antagonist against them as an effective ingredient.
An isolated polypeptide comprising amino acid residues 156 to 686 of SEQ ID NO:
An isolated polypeptide consisting of amino acid residues 460 to 656 of SEQ ID NO:
An isolated soluble meltrin polypeptide which comprises amino acid residues 156 to 686 of SEQ ID NO:12.
An isolated polypeptide comprising amino acid residues 1 to 686 of SEQ ID NO:
An isolated soluble meltrin polypeptide which comprises amino acid residues 1 to 686 of SEQ ID NO:12.
Dependencies are inferred from the claim text.